Amgen needs it, SSRX has it.SSRX is the country's #1 market share leader in the anemia space...and by a sizable margin.SSRX historical earnings (pre and post going public) has consistently proven growth...and very fast growth! Just check out their website & investors page for details.Plain and simple (and my own personal opinion), I continue to believe SSRX is a friggin steal at these prices!The market leader folks -- numero uno -- the kind of leadership a maven like Warren Buffet would scoop up in a heartbeat. If SSRX is not a takeover target, it is at the very least a "partnership play" waiting to happen (I ask you, what big pharma makes the move?).The folks at Motley Fool, IBD (Marilyn Alva), and Kimberly Lee of Pacific Growth Equities seem to be clued-in and recognizing the value. How long before others catch-on?
Hi,I agree, but takeover candidate, no.What other takeovers have you read about of small cap China stocks that sell on NASDAQ? It's just not happening. There are too many rules in Chnia preventing this.Otherwise, you're right on target. The growth is amazing in a growing market, and it's not so dependent on the economy.Cheers!
Hi,One more point, what could happen, and it has happened with other China stocks like The9 NCTY is that a company like Amgen comes in and purchases an interest in the company. Cheers!
After seeing the surprising epo sales from amgen, I am wondering what kind of numbers ssrx will put up in China.